
93 percent of advanced leukaemia patients in remission after immunotherapy
‘Extraordinary’ but short-term results from early-stage trial of engineered immune cells Twenty-seven of 29 patients…
‘Extraordinary’ but short-term results from early-stage trial of engineered immune cells Twenty-seven of 29 patients…